Patent details

LUC00201 Product Name: crizanlizumab

Basic Information

Publication number:
LUC00201
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP131644031
Legal Status:
Inactive
Application number:
LUC00201
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/20/1476
Marketing Authorization Type:
Marketing Authorization Date:
29/10/2020
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
08/04/2021
First Marketing Authorization date:
29/10/2020
Grant date:
29/04/2022
Activation date:
Publication date:
08/04/2021
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
30/11/2032
SPC Extension Expiration:
30/11/2032
Rejection date:
Withdrawal date:

Owner

From:
08/04/2021
 
 

Name:
Novartis AG
Address:
Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Name:
Oklahoma Medical Research Foundation
Address:
825 N.E. 13th Street, Oklahoma City, OK 73104, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
08/04/2021
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC2
Bulletin edition number:
2022/06
Publication date:
03/05/2022
Description:
Section D : Granted supplementary protection certificates – I2 publication

2

Bulletin Heading:
SPC1
Bulletin edition number:
2021/06
Publication date:
04/05/2021
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

Annual Fees

Annual Fee Due Date:
30/11/2027
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
08/04/2021 Summary of the product caracteristics 33
08/04/2021 Marketing authorization 3
08/04/2021 MA publication 7
08/04/2021 Outgoing Correspondence 1
08/04/2021 Application Form 3
08/04/2021 Publication 1
29/04/2022 Publication 1
29/04/2022 Certificate 1
02/05/2022 Outgoing Correspondence 1